Cargando…

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

BACKGROUND: The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower risk of resistance emergence. WHO requested updated modelling results f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Ripin, David, Da Silva, Juliana, Raizes, Elliot, Ford, Nathan, Siberry, George K, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Calmy, Alexandra, Bertagnolio, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167509/ https://www.ncbi.nlm.nih.gov/pubmed/32035041 http://dx.doi.org/10.1016/S2352-3018(19)30400-X

Ejemplares similares

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa
por: Phillips, Andrew N, et al.
Publicado: (2016)

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2017)

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure
por: Shroufi, Amir, et al.
Publicado: (2019)

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile
por: Phillips, Andrew N., et al.
Publicado: (2016)

90‐90‐90 by 2020? Estimation and projection of the adult HIV epidemic and ART programme in Zimbabwe – 2017 to 2020
por: Bansi‐Matharu, Loveleen, et al.
Publicado: (2018)

Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance
por: Phillips, Andrew N, et al.
Publicado: (2019)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2019)

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2017)

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
por: Mofenson, Lynne M, et al.
Publicado: (2019)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Strengthening the scale‐up and uptake of effective interventions for sex workers for population impact in Zimbabwe
por: Cowan, Frances M, et al.
Publicado: (2019)

Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models
por: Bansi-Matharu, Loveleen, et al.
Publicado: (2022)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2016)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
por: Khemla, Supphachoke, et al.
Publicado: (2023)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models
por: Bershteyn, Anna, et al.
Publicado: (2022)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Cost‐effectiveness of routine viral load monitoring in low‐ and middle‐income countries: a systematic review
por: Barnabas, Ruanne V, et al.
Publicado: (2017)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2020)

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2022)

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir
por: Keegan, Michael R., et al.
Publicado: (2018)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study
por: Moolla, Haroon, et al.
Publicado: (2023)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Characteristics and treatment outcomes of tuberculosis patients who “transfer-in” to health facilities in Harare City, Zimbabwe: a descriptive cross-sectional study
por: Takarinda, Kudakwashe C, et al.
Publicado: (2012)

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
por: Belay, Yared Belete, et al.
Publicado: (2021)

Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells
por: George, Joseph W., et al.
Publicado: (2021)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
por: Zhong, Mingli, et al.
Publicado: (2023)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3i8ds6ro39lqur44ncokfcbfc